Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 06 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-oct-06-2022-5

Zydus Lifesciences Limited has informed the Exchange about press release dated 06-Oct-2022 titled Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases